
Tempus AI’s Meteoric Rise: Strategy or Speculative Surge?
Tempus AI’s stock has surged over 160% in the past month, raising questions about sustainable growth vs. overvaluation. The acquisition of Ambry Genetics for $600 million enhances Tempus AI’s presence in genetic diagnostics beyond oncology. Projected revenue growth of roughly 30% annually